LLY compared with GYRE: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

GYREGyre Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

GYREGyre Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

GYRE

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+18.70%—

Q2 FY26±65.8%▲+4.22%×0.06

= impliedLLY realized, solidGYRE realized, hatchedOne scale, both sides: full bar = 66%× = |realized| ÷ impliedSource: market data

May 7 '26

±42.3%

▼−12.06%

×0.29

Q1 FY26±56.7%▼−6.30%×0.11

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

GYREGyre Therapeutics, Inc.

4.75▲+18.58%· post 4.75

ClosedNov 6 '26

Mkt cap$548.9MRevenue$33MQ3 FY26Revenue$120MFY25

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

GYREGyre Therapeutics, Inc.

1,360.90▼−0.28%post 1,358.90

Price

4.75▲+18.58%post 4.75

$1.2T

Mkt cap

$548.9M

Q3 FY26$24.4B

Revenue

$33MQ3 FY26

FY25$65.2B

Revenue

$120MFY25

LLY1,360.90▼−0.28%vsGYRE4.75▲+18.58%ClosedNov 6 '26